secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZyVersa Therapeutics, Inc. (ZVSA)
CIK:        0001859007
Form:       8-K
Filed at:   2023-01-27T23:59:59+00:00
Accession:  0001493152-23-002761
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

ZyVersa grants 100,000-share option inducement to new CMO Dr. Pablo Guzman at $2.11
--------------------------------------------------------------------------------

- Nonqualified stock option to purchase 100,000 shares at $2.11/share, the Jan 25, 2023 closing price.
- Option has 10-year term, vests in three equal annual installments starting Jan 26, 2024, subject to continued service.
- Grant approved by Compensation Committee as inducement material to Dr. Guzman's employment as CMO and SVP of Medical Affairs.
- Inducement award was granted outside ZyVersa's 2022 Equity Incentive Plan under Nasdaq Rule 5635(c)(4).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1859007/000149315223002761/0001493152-23-002761-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1859007/000149315223002761/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-002761

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer